Unnur Bjornsdottir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Unnur Bjornsdottir has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Alan Altraja
Department of Pulmonology University of Tartu and Lung Clinic, Tartu University Hospital Tartu Estonia
1 shared publicationAndrew N. Menzies‐Gow
Royal Brompton & Harefield Hospitals London UK
1 shared publicationAndrey S. Belevskiy
Department of Pulmonology N.I. Pirogov Russian State National Research Medical University Moscow Russian Federation
1 shared publication- Andriana Papaioannou
2nd Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Athens, Greece
1 shared publication Anna von Bulow
Respiratory Research Unit Bispebjerg University Hospital Copenhagen Denmark
1 shared publicationAnthony Newell
Observational and Pragmatic Research Institute Singapore Singapore
1 shared publication
Latest Publications
- Open Access
Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both
Background: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti‐IgE and anti‐IL5/5R and to compare the effectiveness of both classes of treatment in real life.Methods: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti‐IgE and anti‐IL5/5R. The effectiveness of anti‐IgE and anti‐IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long‐term‐oral corticosteroid (LTOCS) use, asthma‐related emergency room (ER) attendance, and hospital admissions.Results: In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti‐IL5/5R group and 38.7% in the anti‐IgE group. Patients treated with anti‐IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti‐IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti‐IL5/5R experienced fewer asthma‐related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43).Conclusions: In real life, both anti‐IgE and anti‐IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti‐IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.
Open AccessComparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both
Background: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti‐IgE and anti‐IL5/5R and to compare the effectiveness of both classes of treatment in real life.Methods: This was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti‐IgE and anti‐IL5/5R. The effectiveness of anti‐IgE and anti‐IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long‐term‐oral corticosteroid (LTOCS) use, asthma‐related emergency room (ER) attendance, and hospital admissions.Results: In the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti‐IL5/5R group and 38.7% in the anti‐IgE group. Patients treated with anti‐IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti‐IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti‐IL5/5R experienced fewer asthma‐related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43).Conclusions: In real life, both anti‐IgE and anti‐IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti‐IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.
- 1 August 1992
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 90 (2) , 202-209
Inhibition of eosinophil density change and leukotriene C4 generation by nedocromil sodium
- 1 August 1992
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 90 (2) , 202-209
Inhibition of eosinophil density change and leukotriene C4 generation by nedocromil sodium